Viral

ALLOVIR, INC. (NASDAQ: ALVR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AlloVir, Inc.

Retrieved on: 
Monday, February 26, 2024
Viral, Court, Action Replay, News, Advertising, Complaint, District court, Virus, Patient, Defendant, Research, Security (finance)

If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.

Key Points: 
  • If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Kirby McInerney LLP Reminds Investors of Lead Plaintiff Deadline in AlloVir, Inc. (ALVR) Securities Class Action

Retrieved on: 
Friday, February 23, 2024
News, Viral, LLP, Virus, Patient, Pharmaceutical industry

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR ) securities during the period of March 22, 2022 through December 21, 2023, inclusive (“the Class Period”).

Key Points: 
  • NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR ) securities during the period of March 22, 2022 through December 21, 2023, inclusive (“the Class Period”).
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
  • Additional information about the firm can be found at Kirby McInerney LLP’s website .

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Retrieved on: 
Wednesday, February 21, 2024
OTCQB, RSV, Virology, Nuclear magnetic resonance, Viral, Vaccine, Lower respiratory tract infection, University, COVID-19, Virus, Patient, Clinical trial, Molar, Carbohydrate, Mutation, Research

BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections. Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.

Key Points: 
  • Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.
  • The multi-center clinical trial in India will be a randomized double-blind placebo-controlled trial and is set to enroll 40 patients.
  • “After we complete the dose optimization trial, the next regulatory milestone is a registrational trial,” said Dr. Leslie Ajayi, Bioxytran’s medical director.
  • “We are on the cusp of completing a clinical trial of standard risk patient that contracted COVID-19.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Retrieved on: 
Wednesday, February 21, 2024
ID, Telephone, Viral

ET to report financial results for the fourth quarter and full year ended December 31, 2023, and to provide a business update.

Key Points: 
  • ET to report financial results for the fourth quarter and full year ended December 31, 2023, and to provide a business update.
  • To access the live conference call, participants may register here .
  • The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com .
  • While not required, it is recommended that participants join the call ten minutes prior to the scheduled start.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR

Retrieved on: 
Tuesday, February 20, 2024
Clinical research associate, Pomerantz, Viral, Court, Person, Prior, News, Complaint, District court, Ext, Virus, Patient, LLP, Action Replay, Research

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ALLOVIR, INC. (NASDAQ: ALVR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AlloVir, Inc.

Retrieved on: 
Tuesday, February 20, 2024
Viral, Court, Action Replay, News, Advertising, Complaint, District court, Virus, Patient, Defendant, Research, Security (finance)

If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.

Key Points: 
  • If you purchased or acquired AlloVir securities, and/or would like to discuss your legal rights and options please visit AlloVir, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Neoplasm, Immune system, Data analysis, Immunotherapy, Cancer, Radioactive decay, Patent, Viral, MicroRNA, Transcoding, RNA, PRR, Vaccine

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) --  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub.

Key Points: 
  • BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) --  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub.
  • The application describes compositions and methods to treat cancer using a novel class of immunotherapy inspired by the innate immunity of mammalian cells against microbes.
  • TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA.
  • Data analysis from the subject dosed in this trial is ongoing and will be included in the final trial report.”

Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Doctor of Philosophy, MD, FDA, Infection, Cryotherapy, Skin, Common, MBA, Finger, Viral, Safety, Nielsen, Wart, Patient, Clinical trial, HPV, FAAD, Trial of the century, Pharmaceutical industry

Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.

Key Points: 
  • Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
  • Nielsen is partnering with Maruho Co. Ltd. (“Maruho”) in the clinical development program for CANDIN.
  • “The first patient treated with CANDIN represents a major milestone for the company, and for patients affected by common warts around the world,” said David P. Burney, PhD, MBA, President and Chief Operating Officer at Nielsen BioSciences.
  • Common warts are estimated to affect approximately 10 percent of the global population.1 There are currently no FDA-approved prescription treatments.

Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, DNA, Methylation, Viral, Orphan drug, GSK, AMG, FDA, Amgen, Indication, Marketing, Proteolysis, Docetaxel, Cell, Proteolysis targeting chimera, Glioblastoma, Therapy, Cancer, TDP1, Half-life, Survival, PRMT5, Acute myeloid leukemia, Research, Pharmaceutical industry

The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.
  • Beyond monotherapies, combination strategies are also being explored in preclinical and clinical trials to enhance PRMT5 inhibition efficacy.
  • However, realizing the full clinical and commercial potential will require validating efficacy and defining suitable patient populations through biomarker-guided trials.
  • Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024 Report Highlights:
    PRMT5 Targeted Therapies Clinical Trials by Company, Indication & Phase
    PRMT5 Targeted Therapies in Clinical Trials: >25
    PRMT5 Targeted Therapies Research & Market Trends by Region: US, UK, EU, China & Canada

Common Immune Response Protective Across Many Diseases

Retrieved on: 
Monday, March 4, 2024
Oncology, Health, Infectious Diseases, General Health, Research, Science, Biotechnology, Paper, ISB, Cancer, Viral, Infection, Multimedia, Inflammation, Systems biology, Lupus, Cell, Death, Prevalence, Autoimmunity, Patient, Disease, NKG2C, Mortality, Immune system, Vaccine

In a just-published paper in the journal Cell Reports , Institute for Systems Biology (ISB) researchers highlight a novel discovery of how the human immune system works in common ways across diseases, and offer promising avenues for exploring multi-disease therapeutic strategies.

Key Points: 
  • In a just-published paper in the journal Cell Reports , Institute for Systems Biology (ISB) researchers highlight a novel discovery of how the human immune system works in common ways across diseases, and offer promising avenues for exploring multi-disease therapeutic strategies.
  • To address these challenges, ISB researchers have identified two immune cell receptors – NKG2A and NKG2C – as factors influencing immune responses across diseases.
  • Through a comprehensive analysis, they found that an NKG2A-dominant immune response correlates with decreased disease severity and mortality, and lower prevalence of post-acute chronic conditions across all disease contexts.
  • The study also identified distinct immune cell profiles associated with NKG2A and NKG2C biases, which could lead to potential therapeutic targets for modifying immune responses across diseases.